Alnylam Pharmaceuticals has been granted a patent for novel cationic lipids that enhance the efficacy and tolerability of in vivo delivery of siRNA. The compounds can be used to form lipid nanoparticles with oligonucleotides, reducing liver toxicity. GlobalData’s report on Alnylam Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Alnylam Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alnylam Pharmaceuticals, siRNA gene silencing was a key innovation area identified from patents. Alnylam Pharmaceuticals's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Novel cationic lipids for lipid nanoparticles with oligonucleotides

Source: United States Patent and Trademark Office (USPTO). Credit: Alnylam Pharmaceuticals Inc

A recently granted patent (Publication Number: US11911475B2) discloses a compound of formula (II) with various specific configurations outlined in the claims. The compound described in the patent includes L1, which can be selected from C4-C24 alkyl and C4-C24 alkenyl, independently substituted with halogen or OH. Additionally, the compound may contain at least two cyclopropyl groups within the alkyl or alkenyl chain, further specifying the range and composition of L1 in the formula.

Furthermore, the patent details the selection of L1 from C4-C24 alkenyl or more specifically from C12-C24 alkenyl with the inclusion of at least one cyclopropyl group. The claims provide a comprehensive overview of the compound's structural variations, allowing for a better understanding of the specific configurations and substitutions permissible within the formula. The patent aims to protect the unique composition and potential applications of the compound, highlighting the importance of these specific structural features in its function and properties.

To know more about GlobalData’s detailed insights on Alnylam Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies